PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 26, 2026Journal of Medicinal Chemistry0 citationsOpen Access

Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader

View Full Paper
DWDimin WuHZHaibin ZhouLBLongchuan Bai

Key Points

  • The study aims to discover and evaluate a selective STAT3 PROTAC degrader for treating human cancers.
  • Designed novel STAT3 PROTAC degraders using high-affinity ligands.
  • Synthesized and tested the potency of SD-965 in mouse models.
  • Administered SD-965 intravenously to evaluate its effects on tumor tissues.
  • SD-965 shows potent and selective degradation of STAT3 without affecting other STAT proteins.
  • It induces rapid and durable depletion of STAT3 in mouse and human tumor models.
  • Achieves tumor regression in leukemia and lymphoma xenografts without signs of toxicity.

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a promising therapeutic target for human cancers and other human diseases. Herein, we report on the design, synthesis, and evaluation of novel STAT3 PROTAC degraders using high-affinity STAT3 ligands and cereblon ligands. Our study led to the discovery of SD-965 as a potent, selective, and efficacious STAT3 degrader. A single intravenous administration of SD-965 effectively induces rapid, complete, and durable depletion of STAT3 protein in mouse native and human xenograft tumor tissues with no depletion of other STAT proteins. SD-965 is capable of achieving tumor regression even with weekly administration in human leukemia and lymphoma xenograft models in mice without any signs of toxicity. SD-965 represents a promising STAT3 degrader for extensive evaluation for the treatment of human cancers and other human diseases.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/69c4cc37fdc3bde448917774https://doi.org/10.1021/acs.jmedchem.5c03767
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases2024 · 79 citations
  2. 2Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression2024 · 26 citations
  3. 3MD-4251: A First-in-Class Oral MDM2 Degrader Inducing Complete Tumor Regression with Single-Dose Administration2025 · 13 citations
  4. 4STAT3 Activation and Oncogenesis in Lymphoma2019 · 88 citations
  5. 5Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation2021 · 218 citations